PARP inhibitors for targeted treatment in ovarian cancer

Mené dans 11 pays sur 564 patients atteintes d'un carcinome ovarien de haut grade sensible aux traitements à base de sels de platine et récidivant, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du rucaparib, un inhibiteur de PARP, en traitement d'entretien après une ou plusieurs lignes de chimiothérapies à base de sels de platine

Résumé en anglais

Poly(ADP-ribose) polymerase (PARP) inhibitors emerged as the first targeted treatment for ovarian cancer, and are selectively active for women with mutations in BRCA1 and BRCA2 (mBRCA). On the basis of data showing activity (measured by the proportion of patients who achieved an objective response),1 the PARP inhibitor olaparib received US Food and Drug Administration (FDA) approval in 2014 specifically for women with germline mBRCA-associated (gBRCA) recurrent ovarian cancer.2 However, subsequent findings from clinical trials of PARP inhibitors have suggested that the importance of mBRCA as a predictive biomarker has diminished.